
Immunic Sets Sights on 2026 Milestones Amid Leadership Overhaul
With top-line data for its lead multiple sclerosis therapy expected by year-end, New York-based Immunic is restructuring its executive ranks. The biotech firm confirmed that its Phase 3 ENSURE trials remain on schedule, supported by a bolstered leadership team and a strengthened balance sheet following recent private financing.



.jpg)





















